Total Funding
23
53
Total FundingSeries B raised
Growth Score
-4 pts
Heat Score
44 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
280901
hVIVO is a contract virology research company that aims to develop antivirals and vaccines in the field of biomedical research.
- Tim Sharpington: Chief Operating Officer
- Cathal Friel: Chairman and Co-FounderPast Role: Amryt Pharma, Co-Founder and Director
About the Company
hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.
hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker ‘HVO’).
